[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nadezhda Women's Health Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":145},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,73,95,119],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100634092","endometrial-immune-profile-changes-after-autologous-intrauterine-prp-treatment-100634092",false,"NCT07535190","Endometrial Immune Profile Changes After Autologous Intrauterine PRP Treatment","Prospective Study on Endometrial Immune Profile Changes After Autologous Intrauterine Platelet Rich Plasma (PRP) Treatment","Inclusion Criteria:\n\n* Participating in Assisted Reproduction Treatment\n* Having infertility\n* Having regular menstrual cycles\n* Embryo transfer of euploid embryos\n\nExclusion Criteria:\n\n* Uterine pathologies\n* Endometrial Bacterial infections\n* Active endometrial inflammation\n* Polycystic ovary syndrome\n* Cancer diagnostics\n* Positive HIV, HCV or HBV tests\n* Autoimmune diseases\n* Recent immune therapy","FEMALE","18 Years","50 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","The success rate after treatment by in-vitro fertilisation (IVF) strongly depends on the endometrial receptivity, which in turn is strictly connected to the endometrial immune profile. IVF outcome is largely dependent upon endometrial immune cell ratios and their relationship with one another.\n\nDuring the last few years there are several studies and case reports for intrauterine PRP application in patients resulting in a thicker, regenerated endometrium and better immune cell population ratios.\n\nIn this project, the investigators aim to analyze the effect of autologous intrauterine PRP administration on the endometrial immune profile, endometrial thickness, selected hormone levels (E2, P4) during the mid-luteal phase and IVF outcomes (biochemical and clinical pregnancy).",[27,28],"IVF Patients","Female Infertility",[30,31,32],"PRP","endometrium","IVF outcomes","RECRUITING","2026-04-14",{"date":36,"type":37},"2026-04-17","ACTUAL",{"date":39,"type":37},"2026-01-19",{"date":41,"type":21},"2028-06",{"name":43,"class":44},"Nadezhda Women's Health Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100498819","effects-of-intrauterine-administration-of-autologous-pbmc-modulated-with-ifnt-on-endometrial-cell-populations-100498819","NCT05775211","Effects of Intrauterine Administration of Autologous PBMC Modulated With IFNt on Endometrial Cell Populations","Effects of Intrauterine Administration of Autologous Peripheral Blood Mononuclear Cells (PBMC) Modulated With Interferon Tau (IFNt) on Endometrial Cell Populations","Inclusion Criteria:\n\n* Participating in Assisted Reproduction Treatment\n* Having primary infertility\n* Having regular menstrual cycles\n* Having signed informed consent\n\nExclusion Criteria:\n\n* Uterine pathologies\n* Endometrial bacterial infections\n* Active endometrial inflammation\n* Polycystic ovary syndrome\n* Presence of auto antibodies such as anti-TPO (thyroid peroxidase), anti-TG (thyroglobulin), ACA (anticentromere antibodies), APA (antiphospholipid antibodies), ANA (antinuclear antibodies), and anti-dsDNA\n* Presence of mutations involving the coagulation system such as deficiency of factor XII, Pro C, Pro S\n* Oncological condition\n* Positive HIV (human immunodeficiency virus), HCV (hepatitis C virus) or HBV (hepatitis B virus) tests",true,{"count":55,"type":21},300,[24],"The aim of this clinical trial is to investigate the change in endometrial composition during the window of implantation following intrauterine administration of PBMC immunomodulated with IFNt.\n\nPatients seeking assisted reproductive therapy will be invited to participate. Two endometrial biopsies will be obtained from each patient during mid-secretory phase of two consecutive menstrual cycles. The first biopsy will be obtained one month before the intervention, and the second one - a day after intrauterine administration of the tested cell treatment which will take place the following month.\n\nImmunohistochemistry analysis of the cell composition of the endometrium will be performed.",[59],"Infertility",[61,62,31,63,64],"intrauterine PBMC","interferon tau","endometrial cell populations","window of implantation","2025-05-20",{"date":67,"type":37},"2025-05-21",{"date":69,"type":37},"2023-03-13",{"date":71,"type":21},"2026-04-28",{"name":43,"class":44},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":94,"locationsCount":45},"100498818","effect-of-intrauterine-administration-of-autologous-pbmc-modulated-with-ifnt-on-ivf-outcome-100498818","NCT05775198","Effect of Intrauterine Administration of Autologous PBMC Modulated With IFNt on IVF Outcome","Effects of Intrauterine Administration of Autologous Peripheral Blood Mononuclear Cells (PBMC) Immunomodulated With Interferon Tau (IFNt) Prior to Embryo Transfer on IVF Outcome","Inclusion Criteria:\n\n* Participating in Assisted Reproduction Treatment\n* Having primary infertility\n* Having regular menstrual cycles\n* Scheduled to undergo embryo transfer of euploid embryos only\n\nExclusion Criteria:\n\n* Uterine pathologies\n* Endometrial bacterial infections\n* Active endometrial inflammation\n* Polycystic ovary syndrome\n* Presence of auto antibodies such as anti-TPO (thyroid peroxidase), anti-TG (thyroglobulin), ACA (anticentromere antibodies), APA (antiphospholipid antibodies), ANA (antinuclear antibodies), and anti-dsDNA\n* Presence of mutations involving the coagulation system such as deficiency of factor XII, Pro C, Pro S\n* Oncological condition\n* Positive HIV (human immunodeficiency virus), HCV (hepatitis C virus) or HBV (hepatitis B virus) tests",{"count":55,"type":21},[24],"The goal of this clinical trial is to test the effect of modulated specialised immune cells isolated from the patients' own blood when administered to the uterus before embryo transfer on the IVF outcome (implantation, pregnancy and live birth rates).\n\nTo achieve this, blood will be obtained from eligible participants. Target cells will be isolated and incubated with the tested modulator for 24h, and returned to the uterine cavity 1 day prior to embryo transfer.\n\nResearchers will compare the reproductive outcome of the tested intervention to that of a control group who will not receive the investigated cell treatment prior to embryo transfer.",[84,85],"Infertility, Female","IVF",[61,62,87,88,89],"implantation","clinical pregnancy","live birth rate",{"date":67,"type":37},{"date":92,"type":37},"2023-03-01",{"date":71,"type":21},{"name":43,"class":44},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":102,"maxAge":18,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},"100471629","effects-of-intrauterine-administration-of-autologous-pbmc-on-the-endometrial-cells-populations-100471629","NCT05421364","Effects of Intrauterine Administration of Autologous PBMC on the Endometrial Cells Populations","Effects of Intrauterine Administration of Autologous Peripheral Blood Mononuclear Cells (PBMC) on the Endometrial Cells Populations","Inclusion Criteria:\n\n* Participating in Assisted Reproduction Treatment\n* Presenting altered endometrial immune profile\n* Having primary infertility\n* Having regular menstrual cycles\n* Embryo transfer of euploid embryos\n\nExclusion Criteria:\n\n* Uterine pathologies\n* Endometrial Bacterial infections\n* Active endometrial inflammation\n* Polycystic ovary syndrome\n* Presence of auto anti-bodies such as anti-TPO, anti-TG, ACA, APA, ANA, and anti-dsDNA\n* Presence of mutations involving the coagulation system such as deficiency of factor XII, Pro C, Pro S\n* Cancer diagnostics\n* Positive HIV, HCV or HBV tests","20 Years",{"count":55,"type":21},[24],"The behaviour of the endometrium during its receptive phase is highly dependent on the endometrial cell type composition. Each cell type has its role in the endometrial preparation for the invading embryo. Alteration in the immune cells dialogue could be the main reason for unsuccessful implantation in certain patients. Immune cell homeostasis is often improved by intrauterine administration of autologous PBMC.\n\nThere have been numerous reports on the positive effects of the intrauterine administration of autologous PBMC on the IVF outcomes (embryo implantation and ongoing pregnancy success). However, there is little data on the direct effect of the PBMC administration on the cell composition of the endometrium. This study will focus on the changes in the endometrial cell populations by PBMC treatment that could lead to IVF outcome improvement.\n\nThe aim of this project is to analyze the effect of intrauterine administration of autologous PBMC on the endometrial cell populations and on the IVF outcome parameters (implantation and ongoing pregnancy success as IVF outcome variables).",[28],[108,109,110,111],"Peripheral blood mononuclear cells (PBMC)","Female infertility","Endometrium","Endometrial cell populations",{"date":67,"type":37},{"date":114,"type":37},"2023-12-09",{"date":116,"type":21},"2026-12-09",{"name":43,"class":44},2,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":126,"maxAge":18,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":118},"100459022","heparin-solution-versus-anti-adhesion-barrier-gel-for-intrauterine-adhesions-prevention-after-operative-hysteroscopy-100459022","NCT05257213","Heparin Solution Versus Anti-adhesion Barrier Gel for Intrauterine Adhesions Prevention After Operative Hysteroscopy","Intrauterine Adhesions Prevention: the Use of Heparin Solution Compared to Application of Anti-adhesion Barrier Gel After Operative Hysteroscopy","Inclusion Criteria:\n\n* female sex\n* indication for operative hysteroscopy including one or more of the following:\n* infertility,\n* irregular bleeding,\n* oligo-\u002Famenorrhea,\n* Asherman syndrome,\n* G0-G3 fibroids,\n* dysmorphic uterus.\n\nExclusion Criteria:\n\n* ongoing pregnancy,\n* genital cancer,\n* pelvic inflammatory disease,\n* excessive uterine bleeding.","25 Years",{"count":128,"type":21},100,[24],"The aim of this study is to compare the efficacy of intrauterine application of heparin solution to the use of hyaluronic acid barrier gel for the prevention of intrauterine adhesion formation after operative hysteroscopy.",[132],"Intrauterine Adhesion",[134,135,136,137,138],"operative hysteroscopy","heparin","anti-adhesion barrier gel","intrauterine adhesion","hyaluronic acid",{"date":67,"type":37},{"date":141,"type":37},"2022-02-14",{"date":143,"type":21},"2026-02-28",{"name":43,"class":44},""]